Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PTH

Peptide · Agonist of parathyroid hormone (PTH) · developed by Entera Bio

Phase 1 Most advanced trial (none active)
ENTX Developer
2 Registered trials

What is PTH?

Teriparatide (PTH) is a parathyroid hormone peptide given by subcutaneous injection. It acts on the parathyroid hormone system, which modulates blood calcium and phosphate concentrations.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Teriparatide
Drug type
Peptide
Targets
parathyroid hormone (PTH)
Mechanism
Agonist of parathyroid hormone (PTH)
Pathways
calcium and phosphate homeostasis
Therapy area
Endocrine
Developer
Entera Bio Ltd. (ENTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03516773 Phase 2 Hypoparathyroidism Completed ENTX
NCT02571140 Phase 1 Drug Safety and Bioavailability Completed ENTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Drug Safety and Bioavailability

More from Entera Bio

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the ENTX page.

Follow ENTX, the company behind PTH

See ENTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ENTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.